...
首页> 外文期刊>Stem cells international >Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence
【24h】

Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence

机译:基于间充质干细胞的肾病治疗:临床证据综述

获取原文
获取原文并翻译 | 示例

摘要

Mesenchymal stem cells form a population of self-renewing, multipotent cells that can be isolated from several tissues. Multiple preclinical studies have demonstrated that the administration of exogenous MSC could prevent renal injury and could promote renal recovery through a series of complex mechanisms, in particular via immunomodulation of the immune system and release of paracrine factors and microvesides. Due to their therapeutic potentials, MSC are being evaluated as a possible player in treatment of human kidney disease, and an increasing number of clinical trials to assess the safety, feasibility, and efficacy of MSC-based therapy in various kidney diseases have been proposed. In the present review, we will summarize the current knowledge on MSC infusion to treat acute kidney injury, chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, systemic lupus erythematosus, and kidney transplantation. The data obtained from these clinical trials will provide further insight into safety, feasibility, and efficacy of MSC-based therapy in renal pathologies and allow the design of consensus protocol for clinical purpose.
机译:间充质干细胞形成自更新的群体,可以从几种组织中分离。多种临床前研究表明,外源MSC的给药可以防止肾损伤,并且可以通过一系列复杂机制促进肾脏恢复,特别是通过免疫系统免疫调节和释放甲克碱因子和微缺血剂。由于其治疗潜力,MSC正在评估为治疗人肾病的可能的球员,并提出了评估MSC基治疗在各种肾病中的安全性,可行性和疗效的越来越多的临床试验。在本综述中,我们将总结当前关于MSC输注的知识,以治疗急性肾损伤,慢性肾病,糖尿病肾病,局灶性节段性肾小球粥样硬化,全身性红斑狼疮和肾移植。从这些临床试验中获得的数据将进一步了解MSC基治疗在肾病理学中的安全性,可行性和功效,并允许设计临床目的的共识方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号